Table 2.

Nonmyeloablative transplantation studies

Exp	Preparative regimen	n	Analysis of c-mpl−/− recipients 3 months after transplantation
			Blood granulocytes, % donor ± SD	Marrow granulocytes, % donor ± SD	Marrow CFU-GMs, % donor ± SD	Marrow HSCs, % donor ± SD*
1	AMD3100	3	26.8 ± 8.0	23.5 ± 4.4	27.7 ± 7.8	5.4 ± 1.6
2	Mock rx	3	24.9 ± 8.9	16.1 ± 3.8	25.1 ± 3.0	1.7 ± 0.5

The percentage donor (ROSA26) HSCs (∗) was determined by the secondary transplantation of marrow cells into irradiated tpo^−/− recipients. See “Results” for details.

rx indicates treatment.